The waylivra market research report is one of a series of new reports that provides waylivra market statistics, including the waylivra industry global market size, regional shares, competitors with the waylivra market share, detailed waylivra market segments, market trends, and opportunities, and any further data you may need to thrive in the waylivra industry. This waylivra market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.
The growth in the forecast period can be attributed to increased global prevalence of rare genetic disorders, expansion of indications, increasing healthcare investment in rare diseases, collaboration with healthcare providers, and the potential for combination therapies. Major trends in the forecast period include personalized treatment models, technological advancements in delivery, advancements in gene therapy, biomanufacturing innovations, remote monitoring, and digital health solutions.
The increasing prevalence of rare genetic disorders is expected to drive the growth of the waylivra market. These disorders are caused by mutations in a person’s DNA and affect a relatively small number of individuals. The rising occurrence of rare genetic disorders can be attributed to advances in genetic testing, better awareness, improved reporting, and wider access to genetic screening and reproductive technologies. Waylivra works by targeting and blocking a protein involved in lipid metabolism, which helps lower blood triglyceride levels. This action helps prevent serious complications such as pancreatitis in affected individuals. For example, in September 2023, a report from the Cystic Fibrosis Trust revealed that the number of people registered with cystic fibrosis, a genetic disorder, surpassed 11,000 in the UK in 2022, a 5% increase compared to the previous year. As such, the growing prevalence of rare genetic disorders is a key driver for the waylivra market.
A significant trend in the waylivra market is gaining regional regulatory approval to meet unmet medical needs and improve global patient access. Regional regulatory approval involves health authorities in specific countries or regions authorizing a drug or medical product to be marketed and sold within that area. For instance, in December 2022, PTC Therapeutics, a US-based biotech company, announced that the Brazilian Health Regulatory Agency (ANVISA) had approved Waylivra (volanesorsen) as the first treatment option for familial partial lipodystrophy (FPL) in Brazil. This approval marked the first global approval of waylivra for treating FPL. Waylivra was also approved in Brazil for treating Familial Chylomicronemia Syndrome (FCS), further expanding its reach.
In January 2024, Acino International AG, a pharmaceutical company based in Switzerland, entered into an exclusive distribution agreement with Sobi, a biopharmaceutical company from Sweden. This partnership focuses on the commercialization of several orphan drugs, including Waylivra, in Kazakhstan. Acino will be responsible for marketing and selling Sobi’s products, including Waylivra, in specialized hospital segments starting in early 2024. This collaboration is expected to expand access to orphan drugs in the region.
The key company operating in the waylivra market is Akcea Therapeutics Inc.
Europe was the largest region in the waylivra market in 2024. The regions covered in waylivra report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.
The countries covered in the waylivra market report are Australia, India, China, South Korea, Japan, UK, France, Germany, USA, Canada.
Waylivra (volanesorsen) is a medication used to treat a rare genetic disorder associated with very high triglyceride levels. It works by inhibiting the production of ApoC-III, a protein that regulates triglyceride metabolism, thereby lowering triglyceride levels and reducing the risk of complications such as pancreatitis.
Note that the outlook for this market is being affected by rapid changes in trade relations and tariffs globally. The report will be updated prior to delivery to reflect the latest status, including revised forecasts and quantified impact analysis. The report’s Recommendations and Conclusions sections will be updated to give strategies for entities dealing with the fast-moving international environment.
The primary indications for waylivra include familial chylomicronemia syndrome (FCS), hypertriglyceridemia, and other rare lipid disorders. Familial chylomicronemia syndrome is a rare genetic condition characterized by extremely high triglyceride levels in the blood, which increases the risk of pancreatitis and other related complications. Waylivra is distributed through various channels, including hospital pharmacies, retail pharmacies, online pharmacies, and specialty pharmacies. It is used by a range of end users, including adults and geriatric patients.
The waylivra market consists of sales of syringes, injection supplies, and patient support programs. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.
The market value is defined as the revenues that enterprises gain from the sale of goods and services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).
The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.
This product will be delivered within 3-5 business days.
The growth in the forecast period can be attributed to increased global prevalence of rare genetic disorders, expansion of indications, increasing healthcare investment in rare diseases, collaboration with healthcare providers, and the potential for combination therapies. Major trends in the forecast period include personalized treatment models, technological advancements in delivery, advancements in gene therapy, biomanufacturing innovations, remote monitoring, and digital health solutions.
The increasing prevalence of rare genetic disorders is expected to drive the growth of the waylivra market. These disorders are caused by mutations in a person’s DNA and affect a relatively small number of individuals. The rising occurrence of rare genetic disorders can be attributed to advances in genetic testing, better awareness, improved reporting, and wider access to genetic screening and reproductive technologies. Waylivra works by targeting and blocking a protein involved in lipid metabolism, which helps lower blood triglyceride levels. This action helps prevent serious complications such as pancreatitis in affected individuals. For example, in September 2023, a report from the Cystic Fibrosis Trust revealed that the number of people registered with cystic fibrosis, a genetic disorder, surpassed 11,000 in the UK in 2022, a 5% increase compared to the previous year. As such, the growing prevalence of rare genetic disorders is a key driver for the waylivra market.
A significant trend in the waylivra market is gaining regional regulatory approval to meet unmet medical needs and improve global patient access. Regional regulatory approval involves health authorities in specific countries or regions authorizing a drug or medical product to be marketed and sold within that area. For instance, in December 2022, PTC Therapeutics, a US-based biotech company, announced that the Brazilian Health Regulatory Agency (ANVISA) had approved Waylivra (volanesorsen) as the first treatment option for familial partial lipodystrophy (FPL) in Brazil. This approval marked the first global approval of waylivra for treating FPL. Waylivra was also approved in Brazil for treating Familial Chylomicronemia Syndrome (FCS), further expanding its reach.
In January 2024, Acino International AG, a pharmaceutical company based in Switzerland, entered into an exclusive distribution agreement with Sobi, a biopharmaceutical company from Sweden. This partnership focuses on the commercialization of several orphan drugs, including Waylivra, in Kazakhstan. Acino will be responsible for marketing and selling Sobi’s products, including Waylivra, in specialized hospital segments starting in early 2024. This collaboration is expected to expand access to orphan drugs in the region.
The key company operating in the waylivra market is Akcea Therapeutics Inc.
Europe was the largest region in the waylivra market in 2024. The regions covered in waylivra report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.
The countries covered in the waylivra market report are Australia, India, China, South Korea, Japan, UK, France, Germany, USA, Canada.
Waylivra (volanesorsen) is a medication used to treat a rare genetic disorder associated with very high triglyceride levels. It works by inhibiting the production of ApoC-III, a protein that regulates triglyceride metabolism, thereby lowering triglyceride levels and reducing the risk of complications such as pancreatitis.
Note that the outlook for this market is being affected by rapid changes in trade relations and tariffs globally. The report will be updated prior to delivery to reflect the latest status, including revised forecasts and quantified impact analysis. The report’s Recommendations and Conclusions sections will be updated to give strategies for entities dealing with the fast-moving international environment.
The primary indications for waylivra include familial chylomicronemia syndrome (FCS), hypertriglyceridemia, and other rare lipid disorders. Familial chylomicronemia syndrome is a rare genetic condition characterized by extremely high triglyceride levels in the blood, which increases the risk of pancreatitis and other related complications. Waylivra is distributed through various channels, including hospital pharmacies, retail pharmacies, online pharmacies, and specialty pharmacies. It is used by a range of end users, including adults and geriatric patients.
The waylivra market consists of sales of syringes, injection supplies, and patient support programs. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.
The market value is defined as the revenues that enterprises gain from the sale of goods and services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).
The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.
This product will be delivered within 3-5 business days.
Table of Contents
1. Executive Summary2. Waylivra Market Characteristics4. Waylivra Market Trends And Strategies5. Waylivra Market - Macro Economic Scenario Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics, Trade Wars and Tariffs, And Covid And Recovery On The Market7. Global Waylivra Pricing Analysis & Forecasts30. Global Waylivra Market Competitive Benchmarking And Dashboard31. Key Mergers And Acquisitions In The Waylivra Market32. Recent Developments In The Waylivra Market
3. Waylivra Market Biologic Drug Characteristics
6. Global Waylivra Growth Analysis And Strategic Analysis Framework
8. Waylivra Market Segmentation
9. Global Waylivra Epidemiology Of Clinical Indications
10. Waylivra Market Regional And Country Analysis
11. Asia-Pacific Waylivra Market
12. China Waylivra Market
13. India Waylivra Market
14. Japan Waylivra Market
15. Australia Waylivra Market
16. South Korea Waylivra Market
17. Western Europe Waylivra Market
18. UK Waylivra Market
19. Germany Waylivra Market
20. France Waylivra Market
21. Eastern Europe Waylivra Market
22. North America Waylivra Market
23. USA Waylivra Market
24. Canada Waylivra Market
25. South America Waylivra Market
26. Middle East Waylivra Market
27. Africa Waylivra Market
28. Waylivra Market Competitive Landscape And Company Profiles
29. Global Waylivra Market Pipeline Analysis
33. Waylivra Market High Potential Countries, Segments and Strategies
34. Appendix
Executive Summary
Waylivra Global Market Report 2025 provides strategists, marketers and senior management with the critical information they need to assess the market.This report focuses on waylivra market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.
Reasons to Purchase:
- Gain a truly global perspective with the most comprehensive report available on this market covering 15 geographies.
- Assess the impact of key macro factors such as conflict, pandemic and recovery, inflation and interest rate environment and the 2nd Trump presidency.
- Create regional and country strategies on the basis of local data and analysis.
- Identify growth segments for investment.
- Outperform competitors using forecast data and the drivers and trends shaping the market.
- Understand customers based on the latest market shares.
- Benchmark performance against key competitors.
- Suitable for supporting your internal and external presentations with reliable high quality data and analysis
- Report will be updated with the latest data and delivered to you along with an Excel data sheet for easy data extraction and analysis.
- All data from the report will also be delivered in an excel dashboard format.
Description
Where is the largest and fastest growing market for waylivra ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The waylivra market global report answers all these questions and many more.The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market’s historic and forecast market growth by geography.
- The market characteristics section of the report defines and explains the market.
- The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
- The forecasts are made after considering the major factors currently impacting the market. These include:
- The forecasts are made after considering the major factors currently impacting the market. These include the Russia-Ukraine war, rising inflation, higher interest rates, and the legacy of the COVID-19 pandemic.
- Market segmentations break down the market into sub markets.
- The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth. It covers the growth trajectory of COVID-19 for all regions, key developed countries and major emerging markets.
- The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
- The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.
Scope
Markets Covered:
1) By Indication: Familial Chylomicronemia Syndrome; Hypertriglyceridemia; Rare Lipid Disorders2) By Distribution Channel: Hospital Pharmacies; Retail Pharmacies; Online Pharmacies; Specialty Pharmacies
3) By End User: Adult; Geriatric
Key Companies Profiled: Akcea Therapeutics Inc.
Countries: Australia, India, China, South Korea, Japan, UK, France, Germany, USA, Canada
Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
Time Series: Five years historic and ten years forecast.
Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita.
Data Segmentation: Country and regional historic and forecast data, market share of competitors, market segments.
Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
Delivery Format: PDF, Word and Excel Data Dashboard.
Companies Mentioned
- Akcea Therapeutics Inc.
